Skip to main navigation
  • About Stoke
    • Overview
    • Leadership
    • Founders
    • Corporate Responsibility
  • Scientific Platform
    • Overview
    • Tango
    • Publications
  • Disease Areas
    • Overview
    • Dravet Syndrome
    • ADOA
    • Rett Syndrome
    • SYNGAP1
    • Pipeline
  • Patients & Families
    • Overview
    • Clinical Studies
    • Expanded Access Policy
    • Educational Resources
  • Careers & Culture
    • Overview
    • Job Opportunities
    • Diversity, Inclusion & Belonging
  • Investors & News
    • Overview
    • Media Room
    • Press Releases
    • Events & Presentations
    • Financials & SEC Filings
    • Stock Information
    • Analyst Coverage
    • Governance
Stoke Therapeutics
  • Contact Us
  • LinkedIn
  • Twitter
  • About Stoke
    • Overview
    • Leadership
    • Founders
    • Corporate Responsibility
  • Scientific Platform
    • Overview
    • Tango
    • Publications
  • Disease Areas
    • Overview
    • Dravet Syndrome
    • ADOA
    • Rett Syndrome
    • SYNGAP1
    • Pipeline
  • Patients & Families
    • Overview
    • Clinical Studies
    • Expanded Access Policy
    • Educational Resources
  • Careers & Culture
    • Overview
    • Job Opportunities
    • Diversity, Inclusion & Belonging
  • Investors & News
    • Overview
    • Media Room
    • Press Releases
    • Events & Presentations
    • Financials & SEC Filings
    • Stock Information
    • Analyst Coverage
    • Governance
  • Home
  • Investors & News
  • Contact IR

Contact IR

Print Page
Email Alerts
Contact IR
Investor FAQs
  • About Stoke
  • Scientific Platform
  • Disease Areas
  • Patients & Families
  • Careers & Culture
  • Investors & News
  • Contact Us
Stoke Logo

© 2023 Stoke Therapeutics, all rights reserved.

  • Privacy Policy
  • Terms of Use
  • Site Map
  • LinkedIn
  • Twitter